· Trial GOIM 2906 - CAPRI "Strategia terapeutica ottimale nei pazienti con tumore del colon retto...

8

Transcript of  · Trial GOIM 2906 - CAPRI "Strategia terapeutica ottimale nei pazienti con tumore del colon retto...

Page 1:  · Trial GOIM 2906 - CAPRI "Strategia terapeutica ottimale nei pazienti con tumore del colon retto metastatico K-ras wild type: cetuximab in associazione con Folfiri seguito da Folfox
Page 2:  · Trial GOIM 2906 - CAPRI "Strategia terapeutica ottimale nei pazienti con tumore del colon retto metastatico K-ras wild type: cetuximab in associazione con Folfiri seguito da Folfox
Page 3:  · Trial GOIM 2906 - CAPRI "Strategia terapeutica ottimale nei pazienti con tumore del colon retto metastatico K-ras wild type: cetuximab in associazione con Folfiri seguito da Folfox
Page 4:  · Trial GOIM 2906 - CAPRI "Strategia terapeutica ottimale nei pazienti con tumore del colon retto metastatico K-ras wild type: cetuximab in associazione con Folfiri seguito da Folfox
Page 5:  · Trial GOIM 2906 - CAPRI "Strategia terapeutica ottimale nei pazienti con tumore del colon retto metastatico K-ras wild type: cetuximab in associazione con Folfiri seguito da Folfox
Page 6:  · Trial GOIM 2906 - CAPRI "Strategia terapeutica ottimale nei pazienti con tumore del colon retto metastatico K-ras wild type: cetuximab in associazione con Folfiri seguito da Folfox
Page 7:  · Trial GOIM 2906 - CAPRI "Strategia terapeutica ottimale nei pazienti con tumore del colon retto metastatico K-ras wild type: cetuximab in associazione con Folfiri seguito da Folfox
Page 8:  · Trial GOIM 2906 - CAPRI "Strategia terapeutica ottimale nei pazienti con tumore del colon retto metastatico K-ras wild type: cetuximab in associazione con Folfiri seguito da Folfox

Www.OncologyEducation.ca KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI.

Www.OncologyEducation.ca KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI.

Updated Safety Data from a Randomized Phase 2 Trial of Hedgehog Pathway Inhibitor GDC-0449 vs. Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients.

Updated Safety Data from a Randomized Phase 2 Trial of Hedgehog Pathway Inhibitor GDC-0449 vs. Placebo with FOLFOX or FOLFIRI and Bevacizumab in Patients.

A Randomized, Double-blind, Placebo-controlled Phase III Study in Patients with Metastatic Colorectal Cancer Receiving First-line Chemotherapy with FOLFOX.

A Randomized, Double-blind, Placebo-controlled Phase III Study in Patients with Metastatic Colorectal Cancer Receiving First-line Chemotherapy with FOLFOX.

DISCUSIÓN...FIRE-3 study design FOLFIRI + Cetuximab Cetuximab: 400 mg/m2 i.v. 120min initial dose 2250 mg/m i.v. 60min q 1w FOLFIRI + Bevacizumab Bevacizumab: 5 mg/kg i.v. 30-90min

DISCUSIÓN...FIRE-3 study design FOLFIRI + Cetuximab Cetuximab: 400 mg/m2 i.v. 120min initial dose 2250 mg/m i.v. 60min q 1w FOLFIRI + Bevacizumab Bevacizumab: 5 mg/kg i.v. 30-90min

FOLFIRI chemotherapy guide

FOLFIRI chemotherapy guide

FOLFOXIRI/ bevacizumab ( bev ) versus FOLFIRI/ bev as first-line treatment in unresectable metastatic

FOLFOXIRI/ bevacizumab ( bev ) versus FOLFIRI/ bev as first-line treatment in unresectable metastatic

PHASE II-III RANDOMISED TRIAL OF DEFINITIVE CHEMORADIOTHERAPY WITH FOLFOX OR CISPLATIN AND FLUOROURACIL IN ESOPHAGEAL CANCER PRODIGE 5 - ACCORD 17 trial:

PHASE II-III RANDOMISED TRIAL OF DEFINITIVE CHEMORADIOTHERAPY WITH FOLFOX OR CISPLATIN AND FLUOROURACIL IN ESOPHAGEAL CANCER PRODIGE 5 - ACCORD 17 trial:

Carcinoma della mammella HER2 positivo metastatico · Unit of Inves,gave Clinical Oncology Is,tuto di Candiolo (IRCCS) Carcinoma della mammella HER2 positivo metastatico

Carcinoma della mammella HER2 positivo metastatico · Unit of Inves,gave Clinical Oncology Is,tuto di Candiolo (IRCCS) Carcinoma della mammella HER2 positivo metastatico

Roma 22 Settembre 2012 La terapia medica del melanoma metastatico Paola Queirolo Dept. Medical Oncology A National Institute for Cancer Research -Genova.

Roma 22 Settembre 2012 La terapia medica del melanoma metastatico Paola Queirolo Dept. Medical Oncology A National Institute for Cancer Research -Genova.

Independent radiological evaluation of objective response ... · N=592 Final RAS evaluable population N= 475 FOLFIRI Cetuximab N= 297 FOLFIRI Bevacizumab N= 295 FOLFIRI Cetuximab

Independent radiological evaluation of objective response ... · N=592 Final RAS evaluable population N= 475 FOLFIRI Cetuximab N= 297 FOLFIRI Bevacizumab N= 295 FOLFIRI Cetuximab

ASCO 2010 CONFIDENTIAL DO NOT DISTRIBUTE Randomized, open-label, phase 3 study of panitumumab (pmab) with FOLFIRI vs FOLFIRI alone as 2nd ‑ line treatment.

ASCO 2010 CONFIDENTIAL DO NOT DISTRIBUTE Randomized, open-label, phase 3 study of panitumumab (pmab) with FOLFIRI vs FOLFIRI alone as 2nd ‑ line treatment.

of FOLFOX/cetuximab or FOLFIRI/cetuximab in a ...news.medlive.cn/uploadfile/20140304/1393914533796.pdf2014/03/04  · Hospital Carl Gustav Carus, Fetscherstr. 74, 01307 Dresden, Germany,

of FOLFOX/cetuximab or FOLFIRI/cetuximab in a ...news.medlive.cn/uploadfile/20140304/1393914533796.pdf2014/03/04  · Hospital Carl Gustav Carus, Fetscherstr. 74, 01307 Dresden, Germany,

Il carcinoma prostatico metastatico: Quale prima linea ...web2.sacrocuore.it/oncologia/Oncologia_18sett15/Settima_Sessione/... · THE NATURAL HISTORY OF METASTATIC PROSTATE CANCER

Il carcinoma prostatico metastatico: Quale prima linea ...web2.sacrocuore.it/oncologia/Oncologia_18sett15/Settima_Sessione/... · THE NATURAL HISTORY OF METASTATIC PROSTATE CANCER

Reduced Duration of Adjuvant FOLFOX in Stage III Colon ...sites.utexas.edu/pharmacotherapy-rounds/files/2017/08/Yeung-E... · Reduced Duration of Adjuvant FOLFOX in Stage III ...

Reduced Duration of Adjuvant FOLFOX in Stage III Colon ...sites.utexas.edu/pharmacotherapy-rounds/files/2017/08/Yeung-E... · Reduced Duration of Adjuvant FOLFOX in Stage III ...

FOLFOX4 (12 cycles) versus sequential dose-dense FOLFOX7 (6 cycles) followed by FOLFIRI (6 cycles) in patients with initially resectable metastatic colorectal.

FOLFOX4 (12 cycles) versus sequential dose-dense FOLFOX7 (6 cycles) followed by FOLFIRI (6 cycles) in patients with initially resectable metastatic colorectal.

RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL ASSESSING SURVIVAL AT 3 YEARS OF POLYVINYL ALCOHOL MICROSPHERES PRELOADED WITH IRINOTECAN (DEBIRI) VS. FOLFIRI.

RESULTS OF A PROSPECTIVE RANDOMIZED TRIAL ASSESSING SURVIVAL AT 3 YEARS OF POLYVINYL ALCOHOL MICROSPHERES PRELOADED WITH IRINOTECAN (DEBIRI) VS. FOLFIRI.

Alternating vs continuous FOLFIRI in advanced colorectal cancer (ACC): a randomized GISCAD trial

Alternating vs continuous FOLFIRI in advanced colorectal cancer (ACC): a randomized GISCAD trial

Company’s · Metastatic Colorectal Cancer (mCRC) patients can be treated with: ̶Conventional Chemotherapy (5 FU, Irinotecan, Oxaliplatin, FolFox, Folfiri) ̶Targeted therapies

Company’s · Metastatic Colorectal Cancer (mCRC) patients can be treated with: ̶Conventional Chemotherapy (5 FU, Irinotecan, Oxaliplatin, FolFox, Folfiri) ̶Targeted therapies

Efficacy of FOLFIRI-3 or other irinotecan-based regimens

Efficacy of FOLFIRI-3 or other irinotecan-based regimens

TERAPIE ONCOLOGICHE · mieloma multiplo e del sarcoma di Kaposi correlato all’AIDS. Myocet: - Trattamento del carcinoma della mammella metastatico. Allora che cardioprotezione scegliamo?

TERAPIE ONCOLOGICHE · mieloma multiplo e del sarcoma di Kaposi correlato all’AIDS. Myocet: - Trattamento del carcinoma della mammella metastatico. Allora che cardioprotezione scegliamo?